Generate Biomedicines (NASDAQ:GENB) Issues Earnings Results

Generate Biomedicines (NASDAQ:GENB) issued its quarterly earnings data on Thursday. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59), Zacks reports.

Generate Biomedicines Stock Up 0.5%

NASDAQ:GENB traded up $0.07 during midday trading on Friday, hitting $13.66. The stock had a trading volume of 291,612 shares, compared to its average volume of 465,861. Generate Biomedicines has a one year low of $11.00 and a one year high of $15.89. The company’s 50-day simple moving average is $12.62.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Zacks Research raised Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. HC Wainwright upped their target price on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday. Morgan Stanley assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $20.00 target price on the stock. Guggenheim assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.